anti-thymocyte globulin
- Generic Name
- anti-thymocyte globulin
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
Phase 1
Recruiting
- Conditions
- Recurrent Severe Aplastic AnemiaRefractory Severe Aplastic Anemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateProcedure: Bone Marrow BiopsyProcedure: Haploidentical Hematopoietic Cell TransplantationOther: Questionnaire Administration
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 6
- Registration Number
- NCT05757310
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
Phase 3
Not yet recruiting
- Conditions
- Engraft FailureRelapseGVHD
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
Phase 1
Recruiting
- Conditions
- Aplastic AnemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveMantle Cell LymphomaPlasma Cell MyelomaChronic Lymphocytic LeukemiaMyelodysplastic SyndromeMyeloproliferative NeoplasmBone Marrow FailureFollicular LymphomaHodgkin Lymphoma
- Interventions
- Biological: Cytokine-treated Veto CellsProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Total-Body Irradiation
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03622788
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT
Phase 2
Completed
- Conditions
- Graft vs Host Disease
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 94
- Registration Number
- NCT02876679
- Locations
- 🇫🇷
Saint Antoine Hospital - Hematology Department, Paris, France
Omental Islet Transplant
Phase 1
Completed
- Conditions
- Type 1 Diabetes
- Interventions
- Procedure: Omental Islet transplant
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 4
- Registration Number
- NCT02821026
- Locations
- 🇨🇦
Clinical Islet Transplant Program, Edmonton, Alberta, Canada
Personalized NK Cell Therapy in CBT
Phase 2
Recruiting
- Conditions
- Acute Myeloid Leukemia With Myelodysplasia-Related ChangesAcute Lymphoblastic LeukemiaISS Stage II Plasma Cell MyelomaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chemotherapy-Related LeukemiaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsISS Stage III Plasma Cell MyelomaChronic Myelomonocytic Leukemia
- Interventions
- Biological: Allogeneic Natural Killer Cell Line NK-92Other: Laboratory Biomarker AnalysisRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT02727803
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Not Applicable
Completed
- Conditions
- Aplastic AnemiaDyskeratosis Congenita
- Interventions
- Biological: Stem Cell TransplantRadiation: Total Body Irradiation
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 61
- Registration Number
- NCT02162420
- Locations
- 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- Refractory Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory T-Cell Non-Hodgkin LymphomaHematopoietic Cell Transplantation Recipient
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological Study
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT01701986
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Phase 2
Recruiting
- Conditions
- Aplastic Anemiade Novo Myelodysplastic SyndromeMyelodysplastic SyndromePreviously Treated Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT01624805
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Scleroderma Treatment With Autologous Transplant (STAT) Study
Phase 2
Completed
- Conditions
- Systemic Scleroderma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01413100
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath